INTRODUCTION
Idiopathic Parkinson's disease (PD) is a progressive neurological disease with many associated movement symptoms. The primary neurochemical basis of the disease is linked to progressive loss of central dopamine containing neurons. This ''dopamine deficiency'' hypothesis is supported by two lines of evidence: (1) Reserpine, which depletes both serotonin (5-HT) and dopamine (DA), has been reported to cause a parkinsonism-like syndrome as a dose dependent side effect (Hornykiewicz, 1973 (Hornykiewicz, , 1993 ; prior to the onset of symptoms there is an 80-95% loss of dopamine in the striatum in PD patients (Hsu and Fahien, 1976; Narabayashi, 1995) ; (2) the discovery of the therapeutic efficacy of levodopa in the alleviation of the symptoms associated with Parkinson's disease.
Although the dopamine deficiency hypothesis is supported by both clinical and pathological findings, this hypothesis alone cannot explain the levodopa failure syndrome (LDFS). This syndrome is characterized by a cluster of symptoms that occur after intensive supplemental administration of levodopa. It is manifested by symptoms either incited by, or unresponsive to levodopa. These symptoms include dyskinesia, motor fluctuations, resistant akinesia, and possible accelerated progression of the disease itself (Cedarbaum and Schleifer, 1990) and various symptoms not classically linked to LDFS but occur with disease progression, such as sleep disturbance, increased fatigue, neuroasthensia, and high prevalence of depression and neurocognative defects, which may reflect the involvement of neurotransmitters besides DA, e.g., 5-HT and norepinephrine. Clinical observations reveal that therapeutic efficacy is lost in greater than 50% of the patients 3 to 5 years after initial treatment with levodopa, and 80% experience some of the motor and cognitive side effects associated with levodopa therapy within a year of the initiation of treatment (Poewe, 1993) .
